/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Evoke Pharma Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$10.93 0.0018(0.18%) EVOK at 04 Dec 2025 04:31 PM Drug Manufacturers - Specialty & Generic
Lowest Today 10.9
Highest Today 10.9
Today’s Open 10.9
Prev. Close 10.91
52 Week High 10.94
52 Week Low 1.94
Day’s Range: Low 10.9 High 10.9
52-Week Range: Low 1.94 High 10.94
1 day return -
1 Week return -
1 month return +2.06
3 month return +106.64
6 month return +263.0
1 year return +161.77
3 year return +505.0
5 year return -70.24
10 year return -

Institutional Holdings

Nantahala Capital Management, LLC 9.51

Bleichroeder LP 4.41

Citadel Advisors Llc 0.80

Fidelity Extended Market Index 0.41

Tower Research Capital LLC 0.13

Vanguard Institutional Extnd Mkt Idx Tr 0.11

Fidelity Series Total Market Index 0.10

Spartan Total Market Index Pool G 0.03

FMR Inc 0.02

Northern Trust Extended Eq Market Idx 0.01

NT Ext Equity Mkt Idx Fd - L 0.01

BlackRock Inc 0.01

NT Ext Equity Mkt Idx Fd - NL 0.01

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.01

SBI Securities Co Ltd 0.00

Morgan Stanley - Brokerage Accounts 0.00

State St US Extended Mkt Indx NL Cl C 0.00

BNYM Mellon SL Market Completion UC1 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

Spartan Extended Market Index Pool F 0.00

Fidelity Total Market Index 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

SSgA U.S. Total Market Index Strategy 0.00

Northern Trust Wilshire 5000 0.00

Goss Wealth Management LLC 0.00

Bank of America Corp 0.00

UBS Group AG 0.00

Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 18.79 M

PB Ratio 5.5787

PE Ratio 0.0

Enterprise Value 12.29 M

Total Assets 17.52 M

Volume 23847

Company Financials

Annual Revenue FY23:4301006 4.3M, FY22:2508645 2.5M, FY21:1618076 1.6M, FY20:23020 0.0M, FY19:0 0.0M

Annual Profit FY23:3968067 4.0M, FY22:2138251 2.1M, FY21:1289958 1.3M, FY20:-63692 -0.1M, FY19:null 0.0M

Annual Net worth FY23:-7608115 -7.6M, FY22:-8162123 -8.2M, FY21:-9029387 -9.0M, FY20:-13261993 -13.3M, FY19:-7096857 -7.1M

Quarterly Revenue Q3/2025:4283979 4.3M, Q2/2025:3752142 3.8M, Q1/2025:3080158 3.1M, Q3/2024:2654186 2.7M, Q2/2024:2551366 2.6M

Quarterly Profit Q3/2025:4182002 4.2M, Q2/2025:3584463 3.6M, Q1/2025:3038545 3.0M, Q3/2024:2550162 2.6M, Q2/2024:2509888 2.5M

Quarterly Net worth Q3/2025:-1156208 -1.2M, Q2/2025:-1570976 -1.6M, Q1/2025:-1306178 -1.3M, Q3/2024:-1312390 -1.3M, Q2/2024:-1267218 -1.3M

Fund house & investment objective

Company Information Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California.

Organisation Drug Manufacturers - Specialty & Generic

Employees 3

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Matthew J. D'Onofrio MBA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow